NRx Defense Systems wins initial $11.18 million DARPA prime contract for SPARC-TMS depression trial

• NRx Defense Systems, a NRX Pharmaceuticals unit, won a DARPA prime contract worth USD 11.18 million for resistant depression research.
• Funding supports the SPARC-TMS study, testing single-day robotic neuronavigated TMS combined with investigational drug NRX-101.
• Trial slated to enroll at McLean Hospital, Arizona State University, HOPE Therapeutics, with planned expansion to military hospitals.
• Program could support an FDA registration package for NRX-101 with TMS in treatment-resistant depression, if results replicate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-032042), on October 05, 2026, and is solely responsible for the information contained therein.